Immunosuppressive strategies for prevention of transplant rejection

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 3, 2001, Pages 377-404

  Dumont, F J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antimetabolites; Immunosuppressants; Inhibitors of T cell activation; Therapeutic monoclonal antibodies; Transplant rejection; Transplantation tolerance; Xenotransplantation

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3,5 BIS(TRIFLUOROMETHYL)PYRAZOLE; A 285222; A 92 308110; BRASILICARDIN A; BRASILINOLIDE A; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IFM 0406; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; JANUS KINASE; MACROLIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEAR FACTOR; OKT 3; PERILLYL ALCOHOL; PNU 156804; PRODIGIOSIN; PROTEIN KINASE (CALCIUM,CALMODULIN); PYRAZOLE DERIVATIVE; RAPAMYCIN; ROSMARINIC ACID; RYANODINE RECEPTOR; SANDIMUNE; SANGLIFEHRIN A; SUCCINIC ACID DERIVATIVE; TACROLIMUS; TAUTOMYCETIN; TERPENOID DERIVATIVE; TRIPTOLIDE; TRIPTOLIDE SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOGRAFT; CAPITAL; CELL INTERACTION; CELL PROLIFERATION; CELL SURFACE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; METHODOLOGY; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NEUROTOXICITY; ORGAN DONOR; ORGAN TRANSPLANTATION; PATENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; XENOTRANSPLANTATION;

EID: 0035114479     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.3.377     Document Type: Review

References (160)

1. Review of transplantation 1999
2. Pancreatic and islet transplantation
3. Immunosuppressive agents in organ transplantation: Past, present and future
4. Cells mediating allograft rejection
5. FK506, an immunosuppressant targeting calcineurin function
6. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center
7. Excerpts from the United States Renal Data System 1999 annual data report
8. Chronic rejection of renal transplants: New clinical insights
9. Mechanisms of chronic rejection
10. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates
11. Molecular biology of transplantation
12. T cell clonal anergy
13. Transplantation tolerance: A look at the nonhuman primate literature in the light of modern tolerance theories
14. Mechanisms of induction of tolerance to organ allografts
15. Prospects for xenotransplantation
16. Signal transduction by the TCR for antigen
17. The immunological synapse and the actin cytoskeleton: Molecular hardware for T cell signaling
18. 2+, calcineurin and NF-AT
19. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes
20. AKAP79 inhibits calcineurin through a site distinct from the immunophilin-binding region
21. Manipulating immune responses with immunosuppressive agents that target NFAT
22. 3,5-bis (trifluoromethyl) pyrazoles: A novel class of NFAT transcription factor regulator
23. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences
24. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation
25. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo
26. Blockade of the lymphocyte voltage-gated potassium channel Kv1.3 as a potential strategy for immunosuppression
27. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3
28. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels
29. Inhibition of T cell proliferation by selective block of Ca(2+)-activated K(+) channels
30. + channel, IKCa1: A potential immuno-suppressant
31. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I
32. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II
33. Ligands for the tyrosine kinase p56lck SH2 domain: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements
34. F2(Pmp)2-TAM zeta 3, a novel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling
35. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70
36. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70
37. Protein kinase C-theta: A new essential superstar on the T-cell stage
38. Perillyl alcohol inhibits TCR-mediated [Ca(2+)](i) signaling, alters cell shape and motility and induces apoptosis in T lymphocytes
39. Phase I pharmacokinetic trial of perillyl alcohol (NSC641066) in patients with refractory solid malignancies
40. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production
41. Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats
42. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
43. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation
44. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor Cells
45. Immunosuppressive activity of the Chinese medicinal plant Tripterygium wilfordii. I. Prolongation of rat cardiac and renal allograft survival by the PG27 extract and immunosuppressive synergy in combination therapy with cyclosporine
46. Immunosuppressive activity of the Chinese medicinal plant Tripterygium wilfordii. II. Prolongation of hamster-to-rat cardiac xenograft survival by combination therapy with the PG27 extract and cyclosporine
47. Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion
48. Inhibition of Type II collagen-induced arthritis in rats by triptolide
49. Inhibitory effect of triptolide on platelet derived growth factor-A and coronary arteriosclerosis after heart transplantation
50. Brasilicardin A, a new terpenoid antibiotic from pathogenic Nocardia brasiliensis: Fermentation, isolation and biological activity
51. Brasilinolide A, a new macrolide antibiotic produced by Nocardia brasiliensis: Producing strain, isolation and biological activity
52. Reversal of anticancer multidrug resistance by the ardeemins
53. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity
54. Mechanism of action of the immunosuppressant rapamycin
55. TOR, a central controller of cell growth
56. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
57. Combined immuno-suppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability
58. Biology of the interleukin-2 receptor
59. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens
60. Synthesis and immunosuppressive activity of novel prodigiosin derivatives
61. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation
62. Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection
63. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents
64. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis
65. Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131)
66. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131[4-(4'hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]
67. Gemcitabine -a novel immunosuppressive agent- prevents rejection in a rat cardiac transplantation model
68. Mycophenolate mofetil and its mechanisms of action
69. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors
70. Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants
71. Prolongation of canine kidney allograft survival with VX-497
72. Selective inhibition of human Molt-4 leukemia Type II inosine 5'-monophosphate dehydrogenase by the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones
73. Purine nucleoside phosphorylase deficiency
74. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice
75. In vivo immunosuppressive effect of purine nucleoside phosphorylase inhibitor-8-amino-9-benzyl-guanine in canine renal allograft rejection
76. Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis
77. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents
78. Leflunomide: Mode of action in the treatment of rheumatoid arthritis
79. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin
80. Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model
81. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin
82. Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin
83. Structure-immunosuppressive activity relationships of new analogues of 15-deoxy spergualin. 1. Structural modifications of the hydroxyglycine moiety
84. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety
85. Tolerance in a rat cardiac allograft model after short-term treatment with LF 08-0299. Absence of clonal deletion and evidence of CD4+ suppressor cells
86. Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues
87. 3 - A hormone with immunomodulatory properties
88. 3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation
89. 3 prolongs graft survival without compromising host resistance to infection or bone mineral density
90. 3 as dose-reducing agents for classical immunosuppressants
91. Signaling and transcription in T helper development
92. Peritransplant tolerance induction with anti-CD3-immunotoxin: A matter of proinflammatory cytokine control
93. On histocompatibility barriers, Th1 to Th2 immune deviation and the nature of the allograft responses
94. Can interleukin-10 be used as a true immunoregulatory cytokine?
95. Regulatory role of Th-2 cytokines, IL-10 and IL-4, in cardiac allograft rejection
96. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection
97. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro
98. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors
99. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells
100. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: Absence of chronic allograft nephropathy
101. Alemtuzumab
102. CAMPATH-1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients
103. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322
104. One year results of tacrolimus (TAC) and anti-CD2 antibody (BTI-322) in adult liver transplantation
105. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells
106. Clinical trials of antibody therapy
107. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival
108. Dominant regulation: A common mechanism of monoclonal antibody induced tolerance?
109. A review of interleukin-2 receptor antagonists in solid organ transplantation
110. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival
111. Selective blockade of IL-15 by soluble IL-15 receptor-alpha chain enhances cardiac allograft survival
112. Reversal of transplant rejection by monoclonal antiblast antibody
113. ABX-CBL monoclonal antibody in patients with steroid resistant graft versus host disease
114. Targeted immunosuppression of alloreactivity with OX-40 immunotoxins
115. Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases
116. Mechanisms of induction of renal allograft tolerance in CD45RB-treated mice
117. CTLA-4 up-regulation plays a role in tolerance mediated by CD45
118. The role of costimulatory molecules as targets for new immunosuppressives in transplantation
119. CD28/CTLA-4 and CD80/CD86 families: Signaling and function
120. BMS-188667
121. CD40-CD40 ligand
122. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
123. The role of CD80, CD86 and CTLA4 in alloimmune responses and the induction of long-term allograft survival
124. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway
125. Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of T cell activation
126. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
127. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154
128. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models
129. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
130. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
131. T cell co-stimulatory molecules other than CD28
132. Adhesion molecules in rejection and tolerance of allografts
133. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules
134. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
135. A single administration of LFA-1 antibody confers prolonged allograft survival
136. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplants
137. A small molecule antagonist of LFA-1-mediated cell adhesion
138. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on lead
139. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding
140. Molecular regulation of integrin function. Block symposium 134
141. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides
142. Chemokines and their receptors in allograft rejection
143. The chemokine/ chemokine-receptor family: Potential and progress for therapeutic intervention
144. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
145. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection
146. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: Blocking monocyte arrest and recruitment
147. Targeting of chemokine receptors CCR2 and CCR5 prolongs murine cardiac allograft survival
148. Requirement of the chemokine receptor CXCR3 for acute allograft rejection
149. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation
150. FTY-720
151. Physiologic and immunologic hurdles to xenotransplantation
152. Potential use of genetically modified pigs as organ donors for transplantation into humans
153. Porcine CTLA4-Ig lacks a MYPPPY Motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7.1
154. Costimulatory blockade by the induction of an endogenous xenospecific antibody response
155. Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts
156. T cell-mediated xenograft rejection: Specific tolerance is probably required for long term xenograft survival
157. Mixed bone marrow chimerism across discordant xenogeneic barriers: The solution for inducing xenotransplant tolerance?
158. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
159. The new immunology - The end of immunosuppressive drug therapy?